Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase RNA writing to reach previously undruggable diseases. The company is developing a first-of-its-kind RNA editing platform that can correct genetic mutations in a safe and reversible way. Co-founders Jacob Borrajo & Basem Al-Shayeb received their Ph.D. at leading institutions for gene editing research: Broad Institute of MIT & Harvard and University of California, Berkeley.